Assertio Holdings Files 8-K/A Amendment

TL;DR

Assertio Holdings filed an amendment to its 8-K, correcting/adding financial details.

AI Summary

Assertio Holdings, Inc. filed an 8-K/A on March 12, 2024, to amend its previous filing regarding results of operations and financial condition, as well as financial statements and exhibits. The earliest event reported was March 8, 2024. The company is incorporated in Delaware and its principal executive offices are located in Lake Forest, Illinois.

Why It Matters

This filing is an amendment to a previous report, indicating that the company is correcting or supplementing information previously disclosed about its financial condition and operations.

Risk Assessment

Risk Level: low — This is a routine amendment to a previous filing, not indicating new negative events.

Key Players & Entities

• Assertio Holdings, Inc. (company) — Registrant
• March 8, 2024 (date) — Earliest event reported
• March 12, 2024 (date) — Filing date
• Delaware (jurisdiction) — State of Incorporation
• Lake Forest, IL (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.0001 — ge on which registered: Common Stock, $0.0001 par value ASRT The Nasdaq Stock Mar
• $1.00 — mum closing bid requirement of at least $1.00 per share; and the Company's ability to

Filing Documents

• tm248562d1_8ka.htm (8-K/A) — 39KB
• tm248562d1_ex99-2.htm (EX-99.2) — 47KB
• 0001104659-24-033520.txt ( ) — 272KB
• asrt-20240308.xsd (EX-101.SCH) — 3KB
• asrt-20240308_lab.xml (EX-101.LAB) — 33KB
• asrt-20240308_pre.xml (EX-101.PRE) — 22KB
• tm248562d1_8ka_htm.xml (XML) — 4KB

02

Item 2.02 Results of Operations and Financial Condition Attached as Exhibit 99.2 hereto, and incorporated by reference herein, is a transcript of the conference call held on March 11, 2024 regarding the Company's fourth quarter and full year 2023 financial results. The information in Item 2.02 of this Amendment shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. The information contained herein shall not be incorporated by reference into any filing with the SEC made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Forward Looking Statements

Forward Looking Statements The statements included in and incorporated by reference into this Amendment include forward-looking statements. Forward-looking statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs. Forward-looking statements speak only as of the date they are made or as of the dates indicated in the statements and should not be relied upon as predictions of future events, as there can be no assurance that the events or circumstances reflected in these statements will be achieved or will occur. Forward-looking statements can often, but not always, be identified by the use of forward-looking terminology including "believes," "expects," "may," "will," "should," "seeks," "intends," "plans," "pro forma," "estimates," "anticipates," "designed," or the negative of these words and phrases, other variations of these words and phrases or comparable terminology. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the statements, including: the Company's ability to grow sales of Rolvedon and the commercial success and market acceptance of Rolvedon and the Company's other products; the Company's ability to successfully develop and execute its sales, marketing and promotion strategies using its sales force and non-personal promotion model capabilities; the impact on sales and profits from the entry and sales of generics of the Company's products and/or other products competitive with any of the Company's products (including indomethacin suppositories compounded by hospitals and other institutions including a 503B compounder which the Company believes to be violation of certain provisions of the Food, Drug and Cosmetic Act); the timing and impact of additional generic approvals and uncertainty around the recent approvals and launches of generic Indocin

01

Item 9.01

Financial Statements and Exhibits

Financial Statements and Exhibits (d) Exhibits Exhibit Number Description 99.2 Transcript of Earnings Conference Call, dated March 11, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ASSERTIO HOLDINGS, INC. Date: March 12, 2024 By: /s/ Ajay Patel Ajay Patel Senior Vice President, Chief Financial Officer (Principal Financial and Accounting Officer)